Natera Inc’s recent filing unveils that its PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon unloaded Company’s shares for reported $0.86 million on Mar 05 ’25. In the deal valued at $143.29 per share,6,000 shares were sold. As a result of this transaction, Moshkevich Solomon now holds 143,768 shares worth roughly $20.22 million.
Then, Chapman Steven Leonard sold 87,272 shares, generating $12,515,006 in total proceeds. Upon selling the shares at $143.40, the CEO AND PRESIDENT now owns 203,354 shares.
Before that, SOLOMON MOSHKEVICH bought 6,000 shares. Natera Inc shares valued at $859,734 were divested by the Officer at a price of $143.29 per share.
Barclays initiated its Natera Inc [NTRA] rating to an Overweight in a research note published on January 23, 2025; the price target was $200. Raymond James revised its rating on February 20, 2024. It rated NTRA as “an Outperform” which previously was an “a Strong buy”.
Price Performance Review of NTRA
On Friday, Natera Inc [NASDAQ:NTRA] saw its stock fall -0.59% to $140.66. Over the last five days, the stock has lost -9.60%. Natera Inc shares have fallen nearly -11.14% since the year began. Nevertheless, the stocks have risen 60.53% over the past one year. While a 52-week high of $183.00 was reached on 01/13/25, a 52-week low of $83.13 was recorded on 03/07/25. SMA at 50 days reached $165.17, while 200 days put it at $135.14.
Levels Of Support And Resistance For NTRA Stock
The 24-hour chart illustrates a support level at 133.99, which if violated will result in even more drops to 127.32. On the upside, there is a resistance level at 145.37. A further resistance level may holdings at 150.08. The Relative Strength Index (RSI) on the 14-day chart is 31.11, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -12.01, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 82.16%. Stochastics %K at 20.99% indicates the stock is a holding.
The most recent change occurred on December 29, 2023 when BTIG Research resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $85.
